The biotechnology landscape is shifting under the feet of established players, and the force behind the tremors is not coming from the usual corridors of Big Pharma or elite academic labs. It is coming from a cohort of young innovators under 35 who are approaching humanity’s most intractable medical problems with a radical blend of audacity, frugality, and interdisciplinary thinking. From a $70 wrap that stops mothers from bleeding to death in Tanzania to AI-generated viruses that can replicate in a petri dish, the breakthroughs emerging from this generation are redefining what is possible in biotech. They are proving that lifesaving technology does not require a billion-dollar budget—it requires a willingness to reimagine the rules.
Each year, MIT Technology Review curates a list of 35 Innovators Under 35, spotlighting researchers and engineers whose work is poised to reshape their fields. The 2026 cohort includes nine individuals working at the frontiers of biotechnology, and their projects span the full arc of human health—from maternal mortality in low-resource settings to the frontiers of epigenetic reprogramming. These are not incremental improvements. They are foundational shifts in how we diagnose, treat, and even reverse disease.
What follows is a deep look at five of these innovators, the mechanisms behind their work, the strategic implications of their breakthroughs, and why each one matters far beyond the laboratory walls.
A $70 Device That Targets the Leading Cause of Maternal Death
Paschal Kija was 28 years old when he developed a device that could save hundreds of thousands of women. His home country, Tanzania, has one of the highest maternal mortality rates in the world, and the single largest contributor is a complication familiar to every obstetrician but devastatingly under-treated in low-resource settings: postpartum hemorrhage.
Postpartum hemorrhage—severe bleeding after childbirth—accounts for roughly 29% of maternal deaths in Tanzania. The standard interventions, including uterotonic drugs and surgical packing, require trained personnel, reliable supply chains, and hospital infrastructure. In rural clinics, those resources are often unavailable. Kija recognized that the problem was not a lack of medical knowledge but a lack of appropriate technology.
His solution is called Mkanda Salama—Swahili for “Safe Wrap.” It is a low-cost, easy-to-use abdominal wrap designed to apply targeted pressure to the uterus, mimicking the physiological mechanism that normally stops bleeding after delivery. The device costs approximately $70 to manufacture, a fraction of the cost of equivalent hospital-based interventions.
In a clinical study, Mkanda Salama stopped postpartum bleeding in 73% of women within 20 minutes of application. That is not just a statistical outcome; it is a practical lifeline for midwives and community health workers who often make the difference between life and death. The device does not require electricity, sterile operating conditions, or advanced medical training. It is designed to work in the context where it is most needed.
Kija’s innovation is a textbook example of frugal engineering—a term that often gets reduced to “making things cheap,” but which actually describes something more profound: designing for constraints. When you cannot assume a reliable supply chain, a sterile environment, or a physician’s presence, you are forced to rethink the problem from first principles. Mkanda Salama is not a stripped-down version of a hospital device. It is an entirely different category of intervention, purpose-built for the environment in which maternal deaths actually occur.
What is the strategic significance here? For global health organizations and governments seeking to meet the Sustainable Development Goal of reducing maternal mortality, Kija’s device offers a scalable, low-barrier tool that can be deployed at the primary care level. For the biotech industry, it serves as a reminder that the next billion-dollar market may not lie in a blockbuster drug but in a $70 device that solves a fundamental problem at scale.
Brain Electrodes That Move Like Neurons
Neural interfaces have been a cornerstone of neuroscience for decades, but they come with a built-in contradiction: to record or stimulate brain activity, you must insert something into the tissue, and that insertion inevitably causes damage. Scar tissue forms. Neurons die. Signal quality degrades. The very act of observation changes the system.
Xiao Yang, 34, is approaching this problem from an entirely different angle. Instead of trying to make electrodes smaller in the conventional sense, she is rethinking their mechanical properties. Her electrodes are ultra-small, yes, but they are also flexible—so flexible, in fact, that they resemble actual neurons in their shape and compliance.
Traditional brain electrodes are rigid. They are made of metal or silicon, materials that do not match the mechanical properties of neural tissue. When the brain moves—and it does, with every heartbeat, every breath, every shift in position—rigid electrodes can shear through delicate neural structures. Yang’s electrodes are designed to move with the brain, reducing the mechanical mismatch that causes tissue damage.
But her most visually striking innovation is a sheet of electrodes inspired by kirigami, the traditional Japanese art of cutting and folding paper to create three-dimensional shapes. The sheet is structured as a honeycomb spiral basket, a geometry that allows the electrode array to expand, contract, and conform to the irregular surface of brain tissue. This is not just an aesthetic choice; it is a functional solution to the problem of maintaining electrical contact with a dynamic, curved biological surface.
Yang is already using these electrode sheets to study brain cells in the lab, and the implications extend far beyond basic neuroscience. Flexible, conformable electrode arrays could eventually enable chronic brain-computer interfaces that do not degrade over time, opening the door to long-term neural recording for prosthetics, epilepsy monitoring, and even cognitive augmentation. For a field that has struggled with the biocompatibility of its implants, Yang’s kir
